<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03809078</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-48151</org_study_id>
    <secondary_id>PROS0091</secondary_id>
    <secondary_id>IRB-48151</secondary_id>
    <secondary_id>NCI-2019-00236</secondary_id>
    <nct_id>NCT03809078</nct_id>
  </id_info>
  <brief_title>A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer</brief_title>
  <official_title>A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrei Iagaru</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>General Electric</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for
      biopsy guidance in patients with suspected prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: To evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for biopsy guidance
      in patients with suspected prostate cancer.

      Exploratory Objective:

        -  Correlation of 68Ga PSMA 11 uptake and Gleason score at biopsy

        -  Correlation of 68Ga RM2 and Gleason score at biopsy
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2019</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PET based Biopsy Guidance</measure>
    <time_frame>12 months</time_frame>
    <description>PET based Biopsy Guidance will be assessed as number of participants with biopsy results correlated with imaging findings (ie, prostate uptake on 68Ga PSMA 11 and 68Ga RM2 scans). The outcome will be reported as the number of participants without dispersion for which PET based biopsy guidance is successfully obtained.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>68Ga RM2 first followed by 68Ga PSMA11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant will be injected IV with 140 ±20% mBq of 68Ga RM2 and then within two weeks Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA11</description>
  </arm_group>
  <arm_group>
    <arm_group_label>68Ga PSMA11 first followed by 68Ga RM2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA11 and then within two weeks Participant will be injected IV with 140 ±20% mBq of 68Ga RM2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga RM2</intervention_name>
    <description>PET radiopharmaceutical</description>
    <arm_group_label>68Ga PSMA11 first followed by 68Ga RM2</arm_group_label>
    <arm_group_label>68Ga RM2 first followed by 68Ga PSMA11</arm_group_label>
    <other_name>68Ga DOTA Bombesin</other_name>
    <other_name>BAY86 7548</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-PSMA-11</intervention_name>
    <description>PET radiopharmaceutical</description>
    <arm_group_label>68Ga PSMA11 first followed by 68Ga RM2</arm_group_label>
    <arm_group_label>68Ga RM2 first followed by 68Ga PSMA11</arm_group_label>
    <other_name>DFKZ 11</other_name>
    <other_name>HBED CC PSMA</other_name>
    <other_name>Heidelberg compound</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Investigational PET scanner coils and software</intervention_name>
    <description>GE Healthcare non-approved PET scanner coils and software</description>
    <arm_group_label>68Ga PSMA11 first followed by 68Ga RM2</arm_group_label>
    <arm_group_label>68Ga RM2 first followed by 68Ga PSMA11</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suspected prostate cancer

          -  Planned prostate biopsy

          -  Able to provide written consent

          -  Karnofsky performance status of 50 (or ECOG/WHO equivalent)

        Exclusion Criteria:

          -  Patients not capable of getting PET study due to weight, claustrophobia, or inability
             to lay still for the duration of the exam

          -  Metallic implants (contraindicated for MRI)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrei H Iagaru, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brittany Williams</last_name>
    <phone>650-497-8588</phone>
    <email>bw718@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Williams</last_name>
      <email>bw718@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Andrei H Iagaru, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carina M Aparici</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruce Daniel</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guido Davidzon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heying Duan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pejman Ghanouni</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Farshad Moradi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geoffrey Sonn</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 16, 2019</study_first_submitted>
  <study_first_submitted_qc>January 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Andrei Iagaru</investigator_full_name>
    <investigator_title>Associate Professor of Radiology (Nuclear Medicine)</investigator_title>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bombesin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

